Dasabuvir CAS# 1132935-63-7 达沙布韦
Dasabuvir, also known as ABT-333, is a non-nucleoside polymerase inhibitor currently under clinical trials for the treatment of Hepatitis C. In the United States, it is approved by the Food and Drug Administration for use in combination with ombitasvir, paritaprevir, and ritonavir in the product Viekira Pak. Dasabuvir acts as a NS5B (an RNA-directed RNA polymerase) inhibitor.
📌 参考资料/链接:
Barnes, David M.; Shekhar, Shashank; Dunn, Travis B.; Barkalow, Jufang H.; Chan, Vincent S.; Franczyk, Thaddeus S.; Haight, Anthony R.; Hengeveld, John E.; Kolaczkowski, Lawrence; Kotecki, Brian J.; Liang, Guangxin; Marek, James C.; McLaughlin, Maureen A.; Montavon, Donna K.; Napier, James J. Discovery and Development of Metal-Catalyzed Coupling Reactions in the Synthesis of Dasabuvir, an HCV-Polymerase Inhibitor. Journal of Organic Chemistry. Volume 84. Issue 8. Pages 4873-4892. Journal; Online Computer File. (2019).
📄 详细内容
CAS No. 1132935-63-7 达沙布韦Dasabuvir synthetic routes

Barnes, David M.; Shekhar, Shashank; Dunn, Travis B.; Barkalow, Jufang H.; Chan, Vincent S.; Franczyk, Thaddeus S.; Haight, Anthony R.; Hengeveld, John E.; Kolaczkowski, Lawrence; Kotecki, Brian J.; Liang, Guangxin; Marek, James C.; McLaughlin, Maureen A.; Montavon, Donna K.; Napier, James J. Discovery and Development of Metal-Catalyzed Coupling Reactions in the Synthesis of Dasabuvir, an HCV-Polymerase Inhibitor. Journal of Organic Chemistry. Volume 84. Issue 8. Pages 4873-4892. Journal; Online Computer File. (2019).
产品链接: CAS No. 1132935-63-7 ››